With CAR T-cell therapy, some of a patient’s own T cells (a type of white blood cell) are removed and genetically modified in a laboratory to recognize their own cancer cells. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancer cells throughout the body. This approach is a form of immunotherapy.
The purpose of this study is to see if the quality of T cells used to make commercial CAR T-cell therapies affects how the CAR T cell prevents cancer from coming back in people with recurrent or persistent multiple myeloma who have had a stem cell transplant. The quality of T cells is dependent on when they were collected. T cells are considered to be high-quality when collected from stem cells (special cells that can develop into different cell types) around the time of the cancer diagnosis and/or from the donor’s cells before chemotherapy treatment.
Patients in this study will receive commercial CAR T cells directed against the BCMA protein on myeloma cells as part of their standard treatment. Researchers will collect samples of the patients’ blood and test the liquid part of the soft tissue inside their bones (bone marrow aspirate) before and after they receive CAR T cells. The investigators will then see how the quality of the T cells in these samples affects the way their cancers respond to CAR T cell treatment.
This trial is currently open and accepting patients.
Enrollment: 32 patients (estimated)View More
View all clinical trial locations sorted by state.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message